Sientra to Participate in COVID-19 Webinar Panel Hosted by Maxim Group

Rhea-AI Summary

Sientra, Inc. (NASDAQ: SIEN) will participate in a virtual panel discussion titled Beauty after the Beast – Aesthetics during COVID-19 on July 16, 2020, at 11:00 a.m. ET, hosted by Maxim Group and M-Vest. The discussion aims to address the impact of the pandemic on medical aesthetics. Sientra specializes in medical aesthetics, offering innovative products like OPUS® breast implants and the miraDry® system. The webinar is part of Maxim’s series focused on re-engaging medical practices during COVID-19. Interested attendees can RSVP via a provided link.

Positive

• Participation in a relevant industry webinar that may enhance brand visibility.
• Showcasing innovative product offerings such as OPUS® breast implants and miraDry® system.

Negative

• None.

SANTA BARBARA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced today that Jeff Nugent, President and Chief Executive Officer, will participate in a virtual webinar panel discussion hosted by Maxim Group and M-Vest on Thursday July 16^th, 2020.The panel discussion, Beauty after the Beast – Aesthetics during COVID-19, is part of Maxim’s COVID-19 Virtual Conference Series: Re-Engaging Medical Practices in an Era of COVID-19.

Panel: Beauty after the Beast – Aesthetics during COVID-19
Date: Thursday, July 16, 2020
Time: 11:00 a.m. ET

To access the panel discussion, please RSVP HERE.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS® breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*) Data on file

Contact
Investor Relations
805-679-8885

FAQ

What virtual event is Sientra participating in on July 16, 2020?

Sientra is participating in a virtual panel discussion titled 'Beauty after the Beast – Aesthetics during COVID-19' on July 16, 2020.

Who is the CEO of Sientra participating in the webinar?

Jeff Nugent, President and CEO of Sientra, will participate in the webinar.

What products does Sientra offer in the medical aesthetics market?

Sientra offers products including OPUS® breast implants and the miraDry® system for underarm sweat and hair reduction.

What is the focus of the panel discussion involving Sientra?

The panel discussion will focus on the impact of COVID-19 on the medical aesthetics industry.